AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30282688 — intervention group
Group type: COMPARATOR
Intervention: Usual care (existing rule-out strategies using serial high-sensitivity troponin testing)
Number of subjects: 594
Study 30282688 — intervention group
Group type: EXPERIMENTAL
Intervention: LoDED strategy
Number of subjects: 594
Study 30282688 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 594
Study 27348903 — intervention group
Group type: EXPERIMENTAL
Intervention: YANG's pricking‐cupping therapy
Number of subjects: 171
Study 27348903 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 171
Study 25308231 — intervention group
Group type: EXPERIMENTAL
Intervention: VK1 solution
Number of subjects: 144
Study 25308231 — intervention group
Group type: COMPARATOR
Intervention: VK1 tablets
Number of subjects: 144
Study 22762168 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebonding of the fractured tooth fragment (Group B)
Number of subjects: 30
Study 22762168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic veneers (Group C)
Number of subjects: 30
Study 22762168 — intervention group
Group type: COMPARATOR
Intervention: Intact teeth (Group A)
Number of subjects: 30
Study 20483024 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive treatment group
Number of subjects: 27
Study 20483024 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment group
Number of subjects: 27
Study 18587731 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly intravenous epoetin alfa
Number of subjects: 289
Study 18587731 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosing of intravenous epoetin alfa or darbepoetin
Number of subjects: 289
Study 15878216 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular Adsorbents Recirculating System (MARS)
Number of subjects: 11
Study 15878216 — intervention group
Group type: COMPARATOR
Intervention: Haemofiltration
Number of subjects: 11
Study 11835638 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin monotherapy after Carbostent implantation
Number of subjects: 110
Study 11835638 — intervention group
Group type: COMPARATOR
Intervention: Combined ticlopidine and aspirin (future comparison group)
Number of subjects: 110
Study 10634963 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon infusion
Number of subjects: 6
Study 10634963 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 6
Study 7770254 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (less than 200 mg/day)
Number of subjects: 11
Study 1975150 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.1 mg/kg)
Number of subjects: 16
Study 1975150 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (0.1 mg/kg)
Number of subjects: 16
Study 1975150 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study 7132652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergometer A
Number of subjects: 10
Study 7132652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergometer B
Number of subjects: 10
Study 7132652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergometer C
Number of subjects: 10
Study 7132652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergometer D
Number of subjects: 10
Study 7132652 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological data
Number of subjects: 10
Study 7132652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergometer A, C, and D
Number of subjects: 10
Study 30739560 — intervention group
Group type: EXPERIMENTAL
Intervention: Collum Femoris Preserving (CFP) stem
Number of subjects: 83
Study 30739560 — intervention group
Group type: COMPARATOR
Intervention: Corail stem
Number of subjects: 83
Study 27550292 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow maxillary expansion (SME)
Number of subjects: 46
Study 27550292 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 46
Study 27550292 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 46
Study 26682997 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (Ω3)
Number of subjects: 23
Study 26682997 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual family psychoeducational psychotherapy (IF-PEP)
Number of subjects: 23
Study 26682997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 26682997 — intervention group
Group type: COMPARATOR
Intervention: Active Monitoring (AM)
Number of subjects: 23
Study 23512912 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin (physiological doses)
Number of subjects: 23
Study 23512912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 23512912 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (post-surgery weight loss)
Number of subjects: 23
Study 21243592 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive approach (MIS)
Number of subjects: 48
Study 21243592 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional approach (KONV)
Number of subjects: 48
Study 21243592 — intervention group
Group type: COMPARATOR
Intervention: Control group (VG)
Number of subjects: 48
Study 19411799 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding Empowerment Program (EG)
Number of subjects: 0
Study 19411799 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 0
Study 17511770 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 10 mg three times daily for 4 weeks
Number of subjects: 60
Study 17511770 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 60
Study 15271125 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants
Number of subjects: 30397
Study 15271125 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 30397
Study 15271125 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 30397
Study 15271125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular drugs
Number of subjects: 30397
Study 15271125 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 30397
Study 15271125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormones
Number of subjects: 30397
Study 15271125 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 30397
Study 15271125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonopioid analgesics (predominantly NSAIDs and acetaminophen)
Number of subjects: 30397
Study 15271125 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-seizure medications
Number of subjects: 30397
Study 15271125 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index
Number of subjects: 30397
Study 15271125 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of scheduled medications
Number of subjects: 30397
Study 15271125 — intervention group
Group type: EXPERIMENTAL
Intervention: Being female and aged 80 and older
Number of subjects: 30397
Study 11878715 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetosalicylic acid (ASA)
Number of subjects: 51
Study 11878715 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 51
Study 11878715 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 51
Study 11878715 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 51
Study 11878715 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of calcium channel blockers and ASA
Number of subjects: 51
Study 11878715 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics and ASA
Number of subjects: 51
Study 11878715 — intervention group
Group type: COMPARATOR
Intervention: Control group (random controls)
Number of subjects: 51
Study 11878715 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental infections rating scales
Number of subjects: 51
Study 9514531 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg daily for 1 year)
Number of subjects: 62
Study 9514531 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical capsule)
Number of subjects: 62
Study 9514531 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 62
Study 9514531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 7997376 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I-Iomazenil SPECT
Number of subjects: 33
Study 7997376 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection of the epileptogenic area
Number of subjects: 33
Study 7997376 — intervention group
Group type: COMPARATOR
Intervention: 99mTc-HMPAO SPECT
Number of subjects: 33
Study 3288680 — intervention group
Group type: EXPERIMENTAL
Intervention: Björk‐Shiley prosthesis
Number of subjects: 575
Study 3288680 — intervention group
Group type: COMPARATOR
Intervention: Hancock heterograft
Number of subjects: 575
Study 3288680 — intervention group
Group type: EXPERIMENTAL
Intervention: Both prostheses
Number of subjects: 575
Study 29052252 — intervention group
Group type: EXPERIMENTAL
Intervention: Social exclusion manipulation (Study 1)
Number of subjects: 234
Study 29052252 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent video game playing (Study 2)
Number of subjects: 234
Study 29052252 — intervention group
Group type: COMPARATOR
Intervention: Nonviolent video game playing (Study 2)
Number of subjects: 234
Study 27167769 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 120
Study 27167769 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (Control)
Number of subjects: 120
Study 24716675 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical subgroup with impulsive traits
Number of subjects: 84
Study 24716675 — intervention group
Group type: EXPERIMENTAL
Intervention: Typically inhibited subgroup
Number of subjects: 84
Study 24716675 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment outcome
Number of subjects: 84
Study 23086295 — intervention group
Group type: EXPERIMENTAL
Intervention: vibroX
Number of subjects: 8
Study 23086295 — intervention group
Group type: COMPARATOR
Intervention: RES
Number of subjects: 8
Study 20179632 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 397
Study 20179632 — intervention group
Group type: COMPARATOR
Intervention: Viscocanalostomy
Number of subjects: 397
Study 17631948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor IV bolus (30 microg/kg) and a 2-hour infusion (4 microg/kg/min) with 600 mg clopidogrel loading dose
Number of subjects: 10
Study 17631948 — intervention group
Group type: COMPARATOR
Intervention: Cangrelor bolus and a 1-hour infusion with 600 mg clopidogrel loading dose
Number of subjects: 10
Study 16777855 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 or 400 mg/day
Number of subjects: 59
Study 16777855 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release paracetamol 1330 mg three times a day
Number of subjects: 59
Study 16777855 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 59
Study 14983653 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (1 mg/2 ml) diluted with 2 ml isotonic sodium chloride
Number of subjects: 73
Study 14983653 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride (4 ml)
Number of subjects: 73
Study 14983653 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (5 mg/2 ml) diluted with 2 ml isotonic sodium chloride
Number of subjects: 73
Study 14983653 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (1 mg/2 ml) and terbutaline (5 mg/2 ml)
Number of subjects: 73
Study 10741293 — intervention group
Group type: EXPERIMENTAL
Intervention: Amenorrhoea
Number of subjects: 126
Study 10741293 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular menstruation
Number of subjects: 126
Study 10741293 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstruation status after chemotherapy
Number of subjects: 126
Study 10741293 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH level
Number of subjects: 126
Study 9083827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of 6 mg heroin hydrochloride
Number of subjects: 4
Study 9083827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of 12 mg heroin hydrochloride
Number of subjects: 4
Study 9083827 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular administration of 6 mg heroin hydrochloride
Number of subjects: 4
Study 8366922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (external insulin pump or three or more daily insulin injections with frequent blood glucose monitoring)
Number of subjects: 1441
Study 8366922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1441
Study 8366922 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (one or two daily insulin injections)
Number of subjects: 1441
Study 3780290 — intervention group
Group type: EXPERIMENTAL
Intervention: ergoloid mesylates (1.5 mg 3-times daily)
Number of subjects: 148
Study 3780290 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 148
Study 31624333 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine treatment
Number of subjects: 338
Study 31624333 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid treatment
Number of subjects: 338
Study 31624333 — intervention group
Group type: EXPERIMENTAL
Intervention: UNC13A genotype
Number of subjects: 338
Study 31624333 — intervention group
Group type: EXPERIMENTAL
Intervention: C9orf72 repeat‐expansion carriers
Number of subjects: 338
Study 29615078 — intervention group
Group type: EXPERIMENTAL
Intervention: Early colonoscopy (performed within 24 h)
Number of subjects: 0
Study 29615078 — intervention group
Group type: COMPARATOR
Intervention: Elective colonoscopy (performed between 24 and 96 h)
Number of subjects: 0
Study 29615078 — intervention group
Group type: EXPERIMENTAL
Intervention: Early colonoscopy
Number of subjects: 0
Study 27906937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transversus abdominis plane block (USG-TAPB) with local anesthetic
Number of subjects: 96
Study 27906937 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided transversus abdominis plane block (USG-TAPB) with saline
Number of subjects: 96
Study 24988203 — intervention group
Group type: EXPERIMENTAL
Intervention: Difaprost®
Number of subjects: 36
Study 24988203 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional therapy)
Number of subjects: 36
Study 22820908 — intervention group
Group type: EXPERIMENTAL
Intervention: ilaprazole (5 mg)
Number of subjects: 12
Study 22820908 — intervention group
Group type: EXPERIMENTAL
Intervention: clarithromycin (500 mg)
Number of subjects: 12
Study 22820908 — intervention group
Group type: EXPERIMENTAL
Intervention: triple therapy (ilaprazole 5 mg, clarithromycin 500 mg, amoxicillin 1 g)
Number of subjects: 12
Study 22820908 — intervention group
Group type: EXPERIMENTAL
Intervention: ilaprazole sulfone
Number of subjects: 12
Study 20523253 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 10 mg
Number of subjects: 70
Study 20523253 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 10 mg plus clonidine 0.15 mg
Number of subjects: 70
Study 20523253 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 15 mg
Number of subjects: 70
Study 20523253 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam plus clonidine 0.15 mg
Number of subjects: 70
Study 20523253 — intervention group
Group type: COMPARATOR
Intervention: midazolam (with or without clonidine)
Number of subjects: 70
Study 20523253 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam plus clonidine
Number of subjects: 70
Study 18477263 — intervention group
Group type: EXPERIMENTAL
Intervention: EXU 3 mg with no passive smoke exposure
Number of subjects: 27
Study 18477263 — intervention group
Group type: EXPERIMENTAL
Intervention: EXU 3 mg after passive smoke exposure (atmospheric nicotine levels 75-125 mug m(‐3) for 2 h)
Number of subjects: 27
Study 16165272 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoE epsilon4 carriers with MCI
Number of subjects: 31
Study 16165272 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers with MCI
Number of subjects: 31
Study 16165272 — intervention group
Group type: COMPARATOR
Intervention: AD patients
Number of subjects: 31
Study 16165272 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 31
Study 12525530 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH physician‐based smoking intervention
Number of subjects: 432
Study 12525530 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 432
Study 10858488 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin (20-40 mg/day, titrated to achieve LDL-cholesterol target of < or =110 mg/dL)
Number of subjects: 6605
Study 10858488 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin
Number of subjects: 6605
Study 8669564 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blockade with bupivacaine
Number of subjects: 31
Study 8669564 — intervention group
Group type: COMPARATOR
Intervention: Control group (no epidural blockade)
Number of subjects: 31
Study 1320987 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nedocromil 4 mg q.i.d. for 8 weeks
Number of subjects: 27
Study 1320987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 6469434 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine
Number of subjects: 30
Study 6469434 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine
Number of subjects: 30
Study 6469434 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 30
Study 31365799 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate transfusion with 20 ml or 30 ml of whole-blood equivalent per kilogram of body weight
Number of subjects: 1565
Study 31365799 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immediate transfusion, transfusion triggered by clinical severity or hemoglobin drop)
Number of subjects: 1565
Study 31365799 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate transfusion
Number of subjects: 1565
Study 31365799 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1565
Study 30445919 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty phenotype assessment
Number of subjects: 235
Study 30445919 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty phenotype assessment with missing data counted as meeting frailty criterion
Number of subjects: 235
Study 27780331 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/day)
Number of subjects: 173
Study 27780331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 24700254 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal PH94B
Number of subjects: 91
Study 24700254 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol spray
Number of subjects: 91
Study 23138167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab 500 mg/m2 every 2 weeks (Group A)
Number of subjects: 61
Study 23138167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab 750 mg/m2 every 2 weeks (Group B)
Number of subjects: 61
Study 23138167 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 61
Study 20363366 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol reinduction (400 mg at weeks 0, 2, and 4)
Number of subjects: 124
Study 17933836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation during bypass (VB)
Number of subjects: 23
Study 17933836 — intervention group
Group type: COMPARATOR
Intervention: Non-ventilation during bypass (NVB)
Number of subjects: 23
Study 15507489 — intervention group
Group type: EXPERIMENTAL
Intervention: Health improvement services targeting mid-life individuals
Number of subjects: 0
Study 15507489 — intervention group
Group type: EXPERIMENTAL
Intervention: Combining free health checks with financial advice
Number of subjects: 0
Study 15507489 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunities to engage in social activities
Number of subjects: 0
Study 15507489 — intervention group
Group type: EXPERIMENTAL
Intervention: Gains in knowledge
Number of subjects: 0
Study 15507489 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of existing knowledge
Number of subjects: 0
Study 11948381 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone 400 microg/d
Number of subjects: 78
Study 11948381 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone 800 microg/d
Number of subjects: 78
Study 11948381 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexamethasone
Number of subjects: 78
Study 9465753 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% pentastarch solution (PS)
Number of subjects: 23
Study 9465753 — intervention group
Group type: COMPARATOR
Intervention: Isotonic 0.9% NaCl solution (IS)
Number of subjects: 23
Study 7629954 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg daily)
Number of subjects: 580
Study 7629954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 580
Study 2664372 — intervention group
Group type: EXPERIMENTAL
Intervention: FAMTX protocol (high dose methotrexate and 5-fluorouracil combined with adriamycin)
Number of subjects: 0
Study 2664372 — intervention group
Group type: COMPARATOR
Intervention: FAM protocol (5-fluorouracil, adriamycin and mitomycin)
Number of subjects: 0
Study 786772 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium amylosulfate (Depepsen)
Number of subjects: 35
Study 786772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 31151306 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD98-M 0.8 g/day
Number of subjects: 51
Study 31151306 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD98-M 1.2 g/day
Number of subjects: 51
Study 31151306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 28240020 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Survival Forest (RSF) approach
Number of subjects: 128
Study 26342188 — intervention group
Group type: EXPERIMENTAL
Intervention: SPA-TLH
Number of subjects: 60
Study 26342188 — intervention group
Group type: COMPARATOR
Intervention: MPA-TLH
Number of subjects: 60
Study 23524476 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction Group (VOAD)
Number of subjects: 32